H2-K1 Knockout cell line (MC38)
Catalog Number: KO01066
Price: Online Inquiry
Catalog Number: KO01066
Price: Online Inquiry
Product Information | |
---|---|
Product Name | H2-K1 Knockout cell line (MC38) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | Epitheloid, semi-adherent semi-suspension cells |
Passage ratio | 1:2-1:4 |
species | Mouse |
Gene | H2-K1 |
Gene ID | 14972 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 90% DMEM+10%FBS |
Parental Cell Line | MC38 |
Quality Control | Genotype: H2-K1 Knockout cell line (MC38) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | histocompatibility 2, K1, K regionprovided by MGI |
Also known as | K-f; H-2K; H2-K; H2-D1; H-2K(d) |
Gene Description | Enables peptide antigen binding activity. Acts upstream of or within several processes, including antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent; antigen processing and presentation of exogenous peptide antigen via MHC class I; and positive regulation of T cell mediated cytotoxicity. Located in external side of plasma membrane. Is expressed in several structures, including brain; genitourinary system; hemolymphoid system gland; liver; and retina. Used to study myositis. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); asthma (multiple); autoimmune disease (multiple); eye disease (multiple); and inner ear disease (multiple). Orthologous to several human genes including HLA-A (major histocompatibility complex, class I, A); HLA-B (major histocompatibility complex, class I, B); and HLA-C (major histocompatibility complex, class I, C). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Broad expression in duodenum adult (RPKM 724.0), mammary gland adult (RPKM 712.4) and 17 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.